NDATOPICALGEL
Approved
Jul 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
XOLEGEL (ketoconazole) by Sandoz is cytochrome p450 3a4 inhibitors [moa]. Approved for tinea pedis, seborrheic dermatitis, candidiasis, vulvovaginal and 1 more indications. First approved in 2006.
Drug data last refreshed 19h ago
Mechanism of Action
Cytochrome P450 3A4 Inhibitors
Worked on XOLEGEL at Sandoz? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.